Humans Mitomycin Gemcitabine Hematuria *Non-Muscle Invasive Bladder Neoplasms Deoxycytidine/therapeutic use Administration Intravesical *Urinary Bladder Neoplasms/drug therapy *Cystitis Chemical cystitis Cistitis química Cáncer de vejiga sin invasión muscular Gemcitabina intravesical Intravesical gemcitabine Intravesical mitomycin Mitomicina intravesical Non-muscle invasive bladder cancer Recurrence rates Tasas de recurrencia

*Carcinoma Renal Cell/complications/epidemiology *Carcinoma Transitional Cell/complications/epidemiology Cross-Sectional Studies Hematuria/epidemiology/etiology Humans Incidence *Kidney Neoplasms/complications/epidemiology Male Prospective Studies Retrospective Studies Risk Factors *Urinary Bladder Neoplasms/complications/epidemiology Age distribution Cystoscopy Haematuria Kidney neoplasms Radiotherapy Sex Smoking Transitional cell carcinoma Urinary bladder neoplasms Urological neoplasms

Bladder cancer Cytology Hematuria Mcm5 Urinary markers to the content of this report.

Humans Administration Intravesical Antibiotics Antineoplastic/administration & dosage Hematuria/drug therapy *Mitomycin/administration & dosage Prospective Studies Quality of Life Treatment Outcome *Urinary Bladder Neoplasms/drug therapy/pathology/surgery

Antineoplastic Agents Alkylating/pharmacology/*therapeutic use Cyclophosphamide/pharmacology/*therapeutic use Female Humans Male Survival Analysis Urinary Bladder Neoplasms/*drug therapy/mortality Cyclophosphamide Hematuria Systematic review Urinary bladder neoplasms

Age Factors Cystoscopy/*methods Cytodiagnosis Hematuria/*complications/*diagnosis Humans Predictive Value of Tests Sex Factors Smoking Time Factors Urinary Bladder Neoplasms/*complications/diagnosis/urine bladder cancer diagnosis haematuria timeliness urinary bladder neoplasm